Liquidia Technologies is trading at $41.33, up 4.12%, with no fresh company-specific announcement or catalyst identified for the October 23 move.
- The October 13 settlement with United Therapeutics resolved six lawsuits, preserved YUTREPIA access for PAH patients, and requires Liquidia to pay net $380.7 million. Coverage describes the continuing rebound as investors digest the deal, but does not establish it as the cause of this sessionβs gain.
- Biotech ETF XBI is down 2.08%, so sector weakness does not explain the rise.